Search results
Results from the WOW.Com Content Network
Valsartan/hydrochlorothiazide, sold under the brand name Diovan HCT among others, is a medication used to treat high blood pressure when valsartan is not sufficient. [6] It is a combination of valsartan, an angiotensin receptor blocker with hydrochlorothiazide , a diuretic . [ 7 ]
Valsartan, sold under the brand name Diovan among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. [8] It belongs to a class of medications referred to as angiotensin II receptor blockers (ARBs). It is a reasonable initial treatment for high blood pressure. [8] It is taken by mouth. [8]
The abrupt drop in sales expected after the date of patent expiration can be estimated with the following formula: [2] S a l e s = A ∗ Y B {\displaystyle Sales={A}*{Y^{B}}} where A is the peak sales value before the patent expiration and Y the years after the peak sales year (the peak sales year is considered year 0), and B is an exponent ...
The number of Adderall and generic equivalent prescriptions has been on the rise over the past few years. In 2021, there were 41.2 million total prescriptions of the drug, a 16% increase from the ...
Rank Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013 Company(ies) Disease/Medical Use First Approval Date Patent Expiration Date [6] [7]; 1: Abilify
Amlodipine/valsartan, sold under the brand name Exforge among others, is a blood pressure lowering combination drug.It contains amlodipine, as the besilate, a dihydropyridine-type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist. [6]
Patheon was founded in Fort Erie, Ontario in 1974 as Custom Pharmaceuticals Ltd. In 1990, it began to expand to US markets. Custom Pharmaceuticals changed its name to Patheon in 1993 and was first publicly traded that year on the Toronto Stock Exchange.
In one main study in adult patients with moderate to severe active Crohn's disease in whom conventional therapy or TNF-alpha antagonists were ineffective or could not be tolerated, vedolizumab was shown to be more effective than placebo: 15% (32 out of 220) of patients receiving vedolizumab showed improved symptoms after 6 weeks of treatment, compared with 7% (10 out of 148) of patients on ...